ABSTRACT
COVID-19 pandemic is a global emergency caused by SARS-CoV-2 infection. Without efficacious antiviral drugs or vaccines available, mass quarantine has been the main strategy adopted by governments to contain the virus spread. This has led to a significant reduction in the number of infected people and deaths and to a diminished pressure over the health care system. However, an economic depression is following due to the forced absence of worker from their job and to the closure of many productive activities. For these reasons, governments are lessening progressively the mass quarantine measures to avoid an economic catastrophe. However, most people has not been yet exposed to the virus, so are susceptible to Covid-19. Therefore, the reopening of firms and commercial activities might lead to a resurgence of infection, as already reported in South Korea and in China were epidemic was considered almost gone although in a few of cases. In the worst-case scenario, this might impose the return to strict lockdown measures. Epidemiological models are therefore necessary to forecast possible new infection outbreaks and to inform government to promptly adopt new containment measures. In this context, we tested here if technical analysis methods commonly used in the financial market might provide early signal of change in the direction of SARS-Cov-2 infection trend in Italy, Iran and Brazil, three countries which have been strongly hit by the pandemic but whose present infection trends are substantially different from each other being therefore particularly useful to understand the potential of TA models. We conclude that technical analysis indicators can be usefully adopted to this aim.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee of Sapienza university of Rome
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.